MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

07/02/2012 by Arezu Sarvestani

Veniti founder, president & CEO Sean Morris tells MassDevice how he intends to conquer the venous disease space with a 3-pronged approach partially inspired by Julius Caesar.

Veniti founder, president & CEO Sean Morris is on the march, looking to take over venous disease treatment with a suit of specialized devices that he hopes will knock out their more generic forebears.

Veniti, formed in 2009, specializes in...

06/26/2012 by Arezu Sarvestani

Venture capitalists are no longer looking for a safe bet - they're on the hunt for disrupters. Managing directors from venture capital firms tell MassDevice where they're looking to place their limited resources and why the old "play-it-safe" model was broken.

The seas are changing for medical device investment.

Venture capitalists are looking at their investment strategies since the 1990s and seeing a broken model focused on funding the familiar, placing safe bets in "incremental" devices...

06/18/2012 by Brian Johnson

MassDevice sits down with Masimo CEO Joe Kiani to discuss his career, his support for President Barack Obama, the medical device tax and what he looks for in a good investment.

Joe Kiani

After a single conversation with Masimo (NSDQ:MASI) founder and CEO Joe Kiani, you realize he's not a man who believes in scaling back his ambitions, or opinions, to suit anyone else.

Kiani started the Irvine, Calif.-based patient monitoring pioneer out of his garage...

06/12/2012 by Brad Perriello

Endosense CEO Jan Keltjens says the company's 3rd-generation TactiCath Quartz ablation catheter, which just won CE Mark approval in the European Union, is "the horse we’re going to ride to the finish line." news

Jan Keltjens is betting Endosense and its TactiCath technology can compete with 1 of the largest players in cardiac ablation: Johnson & Johnson's (NYSE:...

06/04/2012 by Arezu Sarvestani

The trouble with developing an entirely new modality for treating deadly cancers of the head and trunk is that you're frequently explaining what you do and how you do it, but Novocure's tumor-treating electromagnetic fields may help patients with chemo-resistant tumors regain their lives.

William Doyle of Novocure

When Novocure won FDA approval for its Tumor Targeting Field cancer therapy system, the company introduced the oncology world to an entire new modality for treatment.

Cancer patients today are most famliar with surgery, radiation and chemotherapy as thearpy optoins, but certain patients can also opt for Novocure's non-invasive electromagnetic therapy, which promises to stop cancer cells in their tracks without adding a new suite of side...

06/01/2012 by Arezu Sarvestani

Rep. Bill Owens (D-N.Y.), an avid supporter of the Affordable Care Act, tells why he decided this month to co-sponsor Rep. Erik Paulsen's (R-Minn.) medical device tax repeal bill. podcast

Click to play

Rep. Bill Owens (D-N...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp